Meshconomy

Sight Diagnostics

Portable machine-vision point-of-care CBC analyzer from a fingerstick (Sight OLO)

Israel

11-50

Latest event found: 21 Apr 2026 · 6 months ago

Vitality Radar

Insufficient evidence

Current

6M History

Industry

Updated 7 days ago

Pillar Analysis

Presence

The analyst’s view of digital footprint. Shown for context; not part of the score.

Business

Dated funding, customer wins, partnerships and acquisitions made, less down rounds, litigation and regulatory action.

insufficient evidence

Innovation

Dated product launches and regulatory clearances, less products retired.

insufficient evidence

Pulse

Direction: dated events in the last 90 days against the 90 before. 50 is flat.

Capacity

Dated hiring, leadership hires, expansion and certifications, less layoffs, departures and closures.

Strategic Assessment

Strategic Vector

Sight Diagnostics appears to have moved from commercialization of its AI-enabled blood-count platform into severe contraction, with its board dismissing the remaining workforce in April 2026 and closure reportedly imminent.[1] No ownership change was identified in the available results.

Efficiency Ratio

The company demonstrated substantial historical capital and technology output, but its reported shutdown indicates very poor current resource-to-output efficiency.

Evidence Signals

1 negative signal

Layoffs HIGH IMPACT HIGH CONF 21 Apr 2026

The board dismissed approximately 20 remaining employees, leaving Sight Diagnostics on the brink of closure after prolonged layoffs and organizational changes.[1]

View source Israel

Background · older than 12 months

Funding HIGH IMPACT MEDIUM CONF 5 Aug 2020

Sight Diagnostics announced a $71 million Series D round, bringing total reported funding to more than $124 million.[6]

View source Israel

Regulatory Clearance HIGH IMPACT MEDIUM CONF 1 Dec 2019

Sight OLO received FDA 510(k) clearance for use in moderate-complexity laboratories in the United States.[4]

View source United States

About: Israeli AI blood-diagnostics company (HQ Tel Aviv; offices in the US and London), founded in 2011 by Yossi Pollak (CEO) and Daniel Levner. Its flagship Sight OLO is the first FDA-cleared direct-from-fingerstick point-of-care complete-blood-count (CBC) analyzer — a compact ('toaster-oven'-sized) machine-vision instrument that delivers a lab-grade 5-part differential CBC from two drops of blood in minutes, with no reagents or routine calibration. FDA 510(k)-cleared (2019), CE-marked, Health Canada and Australia POC approved; deployed with health systems (incl. Sheba during COVID) and a Pfizer partnership. Raised ~$200M over its history (Koch Disruptive Technologies, OurCrowd, CK Hutchison/Longliv, IFC). The portable, reagent-free CBC is a strong austere/field blood-diagnostics fit for C12. Note: the company has contracted sharply (from ~300 employees to ~11–50) and is repositioning toward an 'immune-intelligence' platform — a materially changed, higher-risk profile.
Tags: #cbc #bloodcount #pointofcare #hematology #machinevision #ai #fda #fingerstick #diagnostics

Suggest an edit